Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CXCR1 | P25024 | 6/20 | 0.60 |
| ▸ | CXCR2 | P25025 | 6/20 | 0.60 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.57 |
| ▸ | NPC1 | O15118 | 1/20 | 0.57 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.57 |
| ▸ | RAB9A | P51151 | 1/20 | 0.57 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.56 |
| ▸ | GABRA5 | P31644 | 1/20 | 0.55 |
| ▸ | LMNA | P02545 | 1/20 | 0.55 |
| ▸ | STAT3 | P40763 | 1/20 | 0.55 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.55 |
| ▸ | P4HTM | Q9NXG6 | 2/20 | 0.55 |
| ▸ | NR1H4 | Q96RI1 | 2/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19074879 | 0.88 | CXCR1 (0.64) | CXCR1CXCR2KDM4ENPC1ALDH1A1 | |
| SCHEMBL9566751 | 0.83 | NPC1 (0.52) | KDM4ENPC1ALDH1A1RAB9ATRPV1 | |
| SCHEMBL4257510 | 0.82 | NR1H4 (0.76) | KDM4ENPC1ALDH1A1RAB9ATRPV1 | |
| SCHEMBL6927893 | 0.81 | CXCR2 (0.68) | CXCR1CXCR2KDM4ENPC1ALDH1A1 | |
| SCHEMBL1461142 | 0.80 | MAPT (0.73) | — | |
| SCHEMBL19074875 | 0.79 | L3MBTL1 (0.66) | CXCR1CXCR2KDM4ENPC1ALDH1A1 | |
| SCHEMBL9306724 | 0.78 | NR1H4 (0.77) | TRPV1LMNASTAT3SMN1; SMN2NR1H4 | |
| SCHEMBL6932337 | 0.78 | GABRA5 (0.51) | GABRA5LMNASTAT3SMN1; SMN2 | |
| SCHEMBL5845966 | 0.78 | CXCR1 (0.80) | CXCR1CXCR2 | |
| SCHEMBL7637674 | 0.78 | NPC1 (0.63) | CXCR1CXCR2KDM4ENPC1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110183980-A1 | O-BENZYL NICOTINAMIDE ANALOGS AS MGLUR5 POSITIVE ALLOSTERIC MODULATORS | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2011-07-28 | — | — | US | disclosed |
| US-20110183980-A1 | O-BENZYL NICOTINAMIDE ANALOGS AS MGLUR5 POSITIVE ALLOSTERIC MODULATORS | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2011-07-28 | — | — | US | disclosed |
| WO-2011035324-A1 | O-BENZYL NICOTINAMIDE ANALOGS AS MGLUR5 POSITIVE ALLOSTERIC MODULATORS | VANDERBILT UNIVERSITY (US) | 2011-03-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110183980-A1 | O-BENZYL NICOTINAMIDE ANALOGS AS MGLUR5 POSITIVE ALLOSTERIC MODULATORS | GRM5, GRIK5, GRM1 | CXCR1 2582/4885CXCR2 2454/4885KDM4E 1200/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.